Tofacitinib Combined With Chidamide in R/R ENKTCL

Updated 06/21/2024

Status Not yet recruiting

Clinical Trial Summary

This study is to explore the efficacy and safety of tofacitinib combined with chidamide in patients with relapsed and refractory extranodal NK/T cell lymphoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03598959
Study type	Interventional
Source	Sichuan University
Contact	Jie Ji, MD
Phone	86-28-85422373
Email	jieji@scu.edu.cn
Status	Not yet recruiting
Phase	Phase 2
Start date	January 1, 2019
Completion date	December 31, 2021

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT04526834` - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma	Phase 1
	Recruiting	`NCT05377827` - Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies	Phase 1
	Recruiting	`NCT04917250` - GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma	Phase 2
	Recruiting	`NCT06406556` - Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL	Phase 2
	Not yet recruiting	`NCT04337593` - Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL	Phase 2
	Active, not recruiting	`NCT04414163` - A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type	Phase 2
	Not yet recruiting	`NCT05700448` - Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma	Phase 3
	Completed	`NCT03246750` - B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma	Phase 1/Phase 2
	Recruiting	`NCT00725231` - Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP	Phase 3
	Recruiting	`NCT04554511` - Prognostic Nomogram of Extranodal NK/T-cell Lymphoma
	Recruiting	`NCT03671850` - VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients	Phase 2
	Completed	`NCT03493451` - Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms	Phase 2
	Recruiting	`NCT04279379` - Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma	Phase 2
	No longer available	`NCT05131438` - An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)